RENO, Nev., Sept. 4, 2012 -- Lifeline Biotechnologies, Inc. (OTC Market: LLBO) announces the award of US Patent #8,226,572 B2 for Methods for Collecting and Analyzing Thermal Data Based on Breast Surface Temperature to Determine Suspect Conditions.
"This Methods patent adds to our core intellectual property along with the device patent we received this past May and for our previously FDA approved 510(k) medical device" says Jim Holmes, Chairman/CEO. "Our basis for originally applying for the three software patents was as a result of the software technical work completed by world renowned pattern recognition specialists we engaged at Nanyang Technological University, Singapore. Once they had modified and improved our technology capabilities to achieve acceptable and competitive accuracy, sensitivity (false positive) and specificity (false negative) utilizing our patient data, we were convinced our processes were patentable. This novel and exciting technology holds the potential to change the way early breast tissue abnormalities and breast cancers are detected" concluded Holmes.
First Warning Systems, Lifeline Biotechnologies' exclusive licensee, is currently updating the patient data collection device and its interpretive software to complete the product package in preparation for market entry. First Warning is conducting a funding round. See firstwarningsystems.com/investors.html for more information.
About First Warning Systems
First Warning Systems, (FWS) founded in 2008, is based in Reno, NV. FWS' principal shareholder is Lifeline Biotechnologies, Inc. Lifeline has licensed FWS with the worldwide exclusive right for development, manufacturing, marketing and commercialization of its intellectual property. The product is a device and process that detects breast tissue abnormalities. Many of these tissue abnormalities will develop into breast diseases, some of which will be breast cancers. The FWS process does not involve compression or radiation and is noninvasive. Three clinical trials with over 650 participants have achieved proof of concept and superior outcomes when compared to other protocols. FWS is planning a final, limited clinical trial and a 510k device classification to validate the fourth generation of the FWS product. FWS is preparing to apply for a Euro CE Mark to market in the UK, EU and Russian markets. See FWS' video, "Breast Cancer Tumor Progression" at www.firstwarningsystems.com/investors.html
About Lifeline Biotechnologies
Lifeline Biotechnologies, Inc. (OTC Market: LLBO) founded in 1994 is based in Reno, NV. LLBO has invested over $10M in a device and process for early detection of breast tissue abnormalities some of which are cancerous or pre-cancer. Three "Proof of Concept" clinical trials of over 650 women have been completed and three patents (one hardware, two software) have been awarded. www.lbti.com.
Lifeline's efforts continue to have DTC remove the chill and allow trading to resume.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, the ability to obtain financing, successful development of the Company's product or market acceptance of the product and regulatory and shareholder approval for anticipated actions.
FOR MORE INFORMATION, CONTACT:
JIM HOLMES, CEO
SOURCE Lifeline Biotechnologies, Inc.